IDT Opens Molecular Biology R&D Facility in Redwood City
Integrated DNA Technologies (IDT) is capitalizing on its expertise to deliver a broader range of validated molecular biology products. R&D for these products will now be performed in a newly built facility in Redwood City, California. The 8000-sq ft building houses labs that will allow IDT scientists to maximize the company’s custom oligonucleotide manufacturing capability.
This new Center of Excellence for R&D keeps IDT on the cutting edge of innovation in molecular biology applications, particularly qPCR, next generation sequencing (NGS), and synthetic biology (SynBio). “For years we’ve focused on enabling research,” said Stephen Gunstream, Chief Commercial Officer. “Redwood City takes that mission to the next level. Now, in addition to our traditional offerings, we will be able to develop complete workflow solutions for cutting edge applications. This provides more value to our customers.”
To lead Redwood City’s Product Development Team, IDT is pleased to announce that Dr Caifu Chen has joined the company as Senior Vice President for R&D. Dr Chen has 25 years of genomics research experience in the academic and biotech sectors, particularly in developing qPCR- and NGS-based assay products for research and diagnostics applications.
“I’m very excited to join the Redwood City team,” said Dr Chen. “We built this new facility for two reasons: One, to have a presence in the Bay Area, which is the worldwide center of the biotech industry. Second, we want to attract top talent that will develop innovative, robust solutions for NGS and qPCR. Robust products equal happier customers. This is our goal.”
“The addition of Dr Chen to our R&D team ensures that our customers can continue to rely on IDT to deliver impactful, high quality products in a timely manner,” said Dr Joseph A. Walder, founder and CEO of IDT. “Dr Chen will build and manage our team of R&D experts who will develop breakthrough genomic solutions.”
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance